DES

• “There remains a large unmet need for transformative technology in cardiovascular intervention to address limitations of coronary artery disease (CAD) treatments such as maintaining the established artery flow lumen, restoring vessel hemodynamic modulation, and stabilizing or regressing plaque to deliver durable and incremental clinical benefit.
• In the absence of restoring artery function, today we see 20% MACE within 5 years1 and 50% by 10 years2 after PCI attributable to non-plateauing annual adverse events with DES,”3 said Motasim Sirhan, CEO of Elixir Medical.
• Featured as an Innovation Session presentation, the clinical results are intended to demonstrate safety and efficacy of Elixir’s lithotripsy technology designed to simplify treatment of a broad range of complex calcified lesions while advancing safety and efficacy of calcium modification.
• Additionally, Elixir Medical will share late-breaking 12-month outcomes of its TRx site-specific antithrombotic therapeutic from the DESyne BDS Plus RCT, a prospective, multicenter, single-blind study evaluating the safety, effectiveness, and performance of the world’s first triple-drug site-specific antithrombotic therapy (TRx) on a DES compared to DESyne X2 Drug-Eluting Coronary Stent System in the treatment of de novo native coronary artery lesions.

• Surface Ophthalmics , a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder & Chairman.
• A highly acclaimed physician and surgeon in ophthalmology, Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, P.A.
• Dr. Lindstrom will lead in partnership with Surface’s distinguished Board of Directors including Adrienne Graves, Ph.D., (Lead Director); Perry J. Sternberg, Shelley Thunen, and J. Andy Corley.
• Dr. Richard Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989.

• Dark energy is estimated to make up nearly 70% of the observable universe, yet we still don’t understand what it is.
• While its nature remains mysterious, the impact of dark energy is felt on grand scales.
• The announcement in New Orleans may take us closer to a better understanding of this form of energy.
• Working out this figure is the first step to really understanding the true nature of dark energy.

Subverting expectations

• The more energy density in the universe, the more repulsion there is – in other words, matter pushes against other matter.
• It might sound a bit bizarre, as it is counterintuitive to everything we experience on Earth.
• The work uses the most direct probe we have on the expansion history of the universe: Type Ia supernovae.
• These distances can then be compared to our expectations.
• This observatory should soon use its telescope to take a first image of the sky following construction, giving a glimpse into its capabilities.

Robert Nichol is a member of the Dark Energy Survey collaboration.

• Revenues for the quarter were $3.84 billion, up 7% compared to the second quarter of 2022.
• Non-GAAP net income was $252 million for the second quarter, up 15% year-over-year, and non-GAAP diluted EPS for the quarter was $1.80, up 13% year-over-year.
• Days Sales Outstanding (DSO) for the quarter was 59, a 3-day improvement from the first quarter of 2023.
• In addition, Leidos returned $50 million to shareholders in the second quarter as part of its regular quarterly cash dividend program.